Results 251 to 260 of about 532,092 (302)

Vascular Endothelial Growth Factor Receptor 2-Targeted Therapy Suppresses the Progression of Alpha-Fetoprotein-Positive Hepatocellular Carcinoma After Combination Therapy With Anti-Programmed Death-Ligand 1 and Anti-Vascular Endothelial Growth Factor-A Antibodies. [PDF]

Gastro Hep Adv
Sugiyama G, Nio K, Okada H, Kida A, Sako K, Iwata Y, Takayama H, Kawakami Y, Chiba T, Nagai K, Sugimoto S, Nishitani M, Hayashi T, Takatori H, Shimakami T, Honda M, Yamashita T.   +16 more
europepmc   +1 more source

Chapter-29 Anti-Vascular Endothelial Growth Factor Therapy

, 2011
openaire   +1 more source

Dissecting VEGFR-2 and VEGFR-3 function : VEGFR-3 mediates lymphangiogenic signals [PDF]

, 2002
Veikkola, Tanja
core  

Cochrane Corner: Anti-vascular endothelial growth factor biosimilar for macular degeneration. [PDF]

Eye (Lond)
Liu SH, Virgili G.
europepmc   +1 more source

Association of plasma metabolites with treatment response after intravitreal anti-vascular endothelial growth factor injections in treatment-naïve neovascular age-related macular degeneration. [PDF]

BMJ Open Ophthalmol
Kang HM, Mendez KM, Laíns I, Sourirajan K, Bhat R, Nigalye A, Katz R, Kozak G, Choi H, Bannerman A, Alvarez RA, Wu D, Kim IK, Liang L, Miller JB, Vavvas DG, Miller JW, Lasky-Su J, Husain D.   +18 more
europepmc   +1 more source

How intravitreal anti-vascular endothelial growth factor initial dosing impacts patient outcomes in diabetic macular oedema. [PDF]

BMC Ophthalmol
Singh RP, Tabano D, Kuo BL, LaPrise A, Leng T, Kim E, Hatfield M, Garmo V.   +7 more
europepmc   +1 more source

Comparison Between Intravitreal Anti-Vascular Endothelial Growth Factor Monotherapy and Vitrectomy in Age-Related Macular Degeneration with Large Submacular Hemorrhages. [PDF]

J Clin Med
Miyazato M, Maruyama-Inoue M, Tanaka S, Inoue T, Yanagi Y, Kadonosono K.   +5 more
europepmc   +1 more source

RETRACTION: Efficacy of Anti-Vascular Endothelial Growth Factor and Mitomycin C on Wound Gealing After Trabeculectomy in Glaucoma Patients: A Meta-Analysis. [PDF]

Int Wound J
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Anti-vascular endothelial growth factor for neovascular glaucoma

Cochrane Database of Systematic Reviews, 2023
Neovascular glaucoma (NVG) is a potentially blinding, secondary glaucoma. It is caused by the formation of abnormal new blood vessels, which prevent normal drainage of aqueous from the anterior segment of the eye. Anti-vascular endothelial growth factor (anti-VEGF) medications are specific inhibitors of the primary mediators of neovascularization ...
Thanitsara, Rittiphairoj, Gloria, Roberti, Manuele, Michelessi   +2 more
openaire   +2 more sources

Anti-Vascular Endothelial Growth Factor Therapy for Radiation Retinopathy

Ophthalmic Surgery, Lasers and Imaging Retina, 2020
BACKGROUND AND OBJECTIVE: The purpose of this article is to review the role of anti-vascular endothelial growth factor (VEGF) therapy in treating patients with radiation retinopathy (RR). PATIENTS AND METHODS: RR can be associated with a significant decrease in visual acuity (VA ...
Nadim, Rayess, Prithvi, Mruthyunjaya
openaire   +2 more sources